David C. Kaslow, MD, is vice president for Essential Medicines, which includes PATH’s Drug Development Program and PATH’s Center for Vaccine Innovation and Access (CVIA). As CVIA Head, David leads PATH’s work to accelerate the development and introduction of high impact vaccines for the most vulnerable children, women, and communities around the world.
David has more than 30 years of experience in product research, development and introduction that spans work in government, biotech, big pharma and non-profit. Before joining PATH in 2012 as Director of PATH Malaria Vaccine Initiative (MVI) to drive the development of safe and effective vaccines against malaria, he was Vice President and Head of Vaccines Project Leadership and Management at Merck Research Laboratories. During this time, he held advisory positions with MVI and the Bill & Melinda Gates Foundation related to malaria vaccines.
David served in the US Public Health Service at the National Institute of Allergy and Infectious Diseases (NIAID), where he was Head, Malaria Vaccine Section and founder of the Malaria Vaccine Development Unit. At NIAID, David completed the molecular cloning and characterization of several proteins involved in malaria parasite sexual development. He also has directed product development, including field studies, of several malaria vaccine candidates. Outside the malaria field, David has contributed to the vaccine application of tools originally developed for gene therapy. He holds or co-holds more than a dozen patents and has published more than 150 scientific papers.
David received his medical degree from the University of California, San Francisco.